Interpace Biosciences Q1 revenue falls

Interpace Biosciences

12/05/2026 21:18

Overview

US thyroid diagnostics firm's Q1 revenue fell 22% yr/yr, but rose 14% on pro forma basis

Adjusted EBITDA for Q1 doubled yr/yr on pro forma basis, gross margin expanded to 65%

Outlook

Company reaffirms 2026 guidance of approximately 16% year-over-year thyroid revenue growth

Interpace expects continued margin expansion through 2026 as volume grows and automation initiatives scale

Company aims to expand thyroid test volume by deeper adoption, more accounts, and productivity gains

Result Drivers

THYROID TEST GROWTH - Co said Q1 thyroid test volume rose 10% yr/yr and thyroid revenue increased 12% yr/yr, driven by expanded clinical adoption and commercial execution

OPERATIONAL EFFICIENCY - Co attributed margin expansion and improved operating leverage to its transition to a thyroid-only diagnostics model and productivity initiatives such as laboratory automation

ACCOUNT AND PRODUCTIVITY GAINS - Co reported increases in average revenue per test, number of accounts, and turnaround time, supporting Q1 performance

Company press release: ID:nGNX2SzLtL

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$9.03 mln
Q1 Net Income
$721,000
Q1 Gross Profit
$5.90 mln
Q1 Operating Expenses
$4.78 mln
Q1 Operating Income
$1.12 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)